<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393417</url>
  </required_header>
  <id_info>
    <org_study_id>CFW-2D</org_study_id>
    <nct_id>NCT02393417</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)</brief_title>
  <official_title>A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nielsen BioSciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nielsen BioSciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, double-blind (subject, Investigator, and site staff with the
      exception of unblinded dedicated staff to handle study medication), phase 2a study with 3
      dose cohorts, randomized (concealed) to CANDIN or placebo (3:1). Main study will be up to 20
      weeks (10 doses administered every other week) or until a subject has complete resolution of
      all injectable common warts. Subjects who cannot tolerate dosing every 2 weeks due to a local
      tolerance issue may be injected at 3-week intervals for up to 10 doses, increasing the length
      of the study to 29 weeks. Subjects will be followed for 4 months after final injection(s) for
      evidence of new or reoccurring warts and for safety evaluation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit</measure>
    <time_frame>45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Complete Resolution of All Common Warts at Any Treatment or Follow-up Visit</measure>
    <time_frame>45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Complete Resolution of Primary Injected Wart(s) at the 4 Month Follow-up Visit</measure>
    <time_frame>4 month follow up visit at 45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Injection Visits Needed to Obtain Complete Resolution of the Primary Injected Wart(s)</measure>
    <time_frame>45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Injection Visits for &gt;50% Reduction in Area of the Primary Injected Wart(s)</measure>
    <time_frame>45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Injection Visits to &gt;50% Reduction in the Total Area of All Measured Warts</measure>
    <time_frame>45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Scarring at the Site of Resolved Primary and Non-primary Injected Wart(s)</measure>
    <time_frame>45 weeks</time_frame>
    <description>Scarring at any visit, many reports were transient being noted at only one or two visits and noted as resolving during the course of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hypopigmentation at the Site of Resolved Primary and Non-primary Injected Wart(s)</measure>
    <time_frame>45 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Injection Site Reactions With Frequency Greater Than 5%</measure>
    <time_frame>45 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Association Between the Age of the Largest Primary Injected Wart and Complete Resolution of the Largest Primary Injected Wart</measure>
    <time_frame>45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </other_outcome>
  <other_outcome>
    <measure>Association Between the Age of the Primary Injected Wart and the Recurrence of Any Resolved Wart at Any Visit.</measure>
    <time_frame>45 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Summary of Complete Resolution of the Largest Primary Wart and Type of Treatment History</measure>
    <time_frame>45 weeks</time_frame>
    <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
  </other_outcome>
  <other_outcome>
    <measure>The Effect of the Treatment History on the Number of Recurrences of Resolved Primary Warts</measure>
    <time_frame>45 weeks</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Warts</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mL of CANDIN administered intralesionally in the largest common wart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of CANDIN administered intralesionally in the largest common wart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pooled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CANDIN</intervention_name>
    <description>Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride Injection USP (non-preserved)</description>
    <arm_group_label>Pooled Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women between the ages of 18 and 65 years inclusively at time of consent

          2. Subjects presenting with 3 to 20 injectable common warts (verruca vulgaris) for at
             least 12 weeks at the time of the Baseline Visit

          3. Subject's common warts for injection must measure between 3 and 20 mm at Baseline
             Visit and be located on hands, feet (excluding soles), limbs, and/or trunk. Flat,
             plantar, facial, periungual, genital warts or warts in region of pre-existing
             inflammatory condition are excluded from injection

          4. Subjects enrolled into Cohort 3 must have common warts for injection in at least 2
             different anatomical regions defined as: left arm, right arm, left hand, right hand,
             left leg, right leg, left foot (excluding sole), right foot (excluding sole) and torso

          5. Subject, male or female is willing to use effective contraceptive method for at least
             30 days before the Baseline Visit and at least 30 days after the last study drug
             administration unless not of childbearing potential as defined as post-menopausal for
             at least 2 years (females) or surgically sterile (tubal ligation, oophorectomy, or
             hysterectomy for females, and vasectomy for males). The only contraceptive use
             exceptions would be individuals in exclusive same sex partnerships and individuals who
             agree to remain non-sexually active for the duration of the study. Acceptable
             contraceptive methods for subjects include:

               -  Barrier methods, such as condom, sponge or diaphragm, combined with spermicide in
                  foam, gel or cream;

               -  Hormonal contraception (oral, intramuscular, implant or transdermal which
                  includes Depo-Provera, Evra and Nuvaring);

               -  Intrauterine device (IUD)

          6. Mentally and legally capable of giving informed consent prior to any study related
             procedures

        Exclusion Criteria:

          1. Presence of systemic or localized diseases, conditions, or medications that could
             interfere with assessment of safety and efficacy or that compromise immune function
             including psoriasis

          2. Subject has been diagnosed with diabetes mellitus

          3. Subject has a history of keloid formation

          4. Injectable common wart(s) located in areas with existing dermatologic conditions (such
             as psoriasis) or with an underlying inflammatory conditions (such as arthritic
             joints), or tattoos or implants/piercing/hardware or marking that may conceal
             responses or reactions are excluded from injection

          5. Existing/planned pregnancy, childbirth in the past six months prior to the Baseline
             Visit, or breast feeding, or plan on donating eggs or sperm during the study and in
             the month following the last injection

          6. Treatment of warts with liquid nitrogen, carbon dioxide, electrodessication, laser,
             surgery, simple occlusion (e.g. duct tape) salicylic or related acids, OTC treatments,
             cantharidin, or other treatments within 4 weeks of the Baseline Visit

          7. Treatment with immunotherapy (DPCP, DNCB or other), imiquimod, 5-fluorouracil,
             bleomycin, podophyllin or any other wart immunotherapy or treatment designed to
             stimulate immune response (except for treatments already listed in exclusion criterion
             6) within 12 weeks of the Baseline Visit

          8. Recalcitrant warts defined as those not successfully treated by 5 or more treatments
             (excluding OTC treatments)

          9. Abnormal (low &lt; 5 mm or high &gt;25 mm) baseline result to the Delayed Type
             Hypersensitivity (DTH) test

         10. Subject has a condition or treatment resulting in being immunocompromised

         11. Systemic treatment (such as oral or injected) with cimetidine, zinc supplements at a
             dose higher than 20 mg of elemental zinc daily or an immunosuppressive drug (such as:
             azathioprine, 6-mercaptopurine, methotrexate, infliximab, adalimumab, etanercept,
             systemic steroids, etc.) within 12 weeks of the Baseline Visit

         12. Subject has used any investigational agent within 30 days prior to the Baseline Visit
             or within 5 half-lives of that investigational agent prior to the Baseline Visit
             (whichever is longer)

         13. Previous treatment of warts with any type of intralesional injection with candida
             extract (including CANDIN)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Carpenter, DVM, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nielsen BioSciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Arkansas Clinical Trials Center PLLC</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Dermatology and Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverberg MD Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical Partners, LLC</name>
      <address>
        <city>Needham</city>
        <state>Massachusetts</state>
        <zip>02492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayState Clinical Trials</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology Clinical Trials</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education and Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec;146(12):1431-3. doi: 10.1001/archdermatol.2010.350.</citation>
    <PMID>21173332</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2019</results_first_posted>
  <last_update_submitted>May 10, 2019</last_update_submitted>
  <last_update_submitted_qc>May 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Verruca vulgaris</keyword>
  <keyword>Common Warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02393417/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02393417/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Screen Fail Rate of 30% - 12% due to warts not meeting criteria, 12% due to DTH measurement not meeting criteria, 5% other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pooled Placebo</title>
          <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1</title>
          <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2</title>
          <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3</title>
          <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT- modified Intent to Treat population consisted of subjects that received at least one post baseline measurement of the primary wart(s).</population>
      <group_list>
        <group group_id="B1">
          <title>Pooled Placebo</title>
          <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1</title>
          <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2</title>
          <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3</title>
          <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="166"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.7" lower_limit="18" upper_limit="65"/>
                    <measurement group_id="B2" value="35.6" lower_limit="19" upper_limit="63"/>
                    <measurement group_id="B3" value="33.5" lower_limit="18" upper_limit="62"/>
                    <measurement group_id="B4" value="30.2" lower_limit="18" upper_limit="54"/>
                    <measurement group_id="B5" value="33.6" lower_limit="18" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Response (size of induration) to CANDIN injection during screening</title>
          <description>CANDIN is currently marketed in the US and was used as indicated in this study as a recall antigen for detecting delayed-type hypersensitivity (DTH) following intradermal injection of 0.1 mL.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.95" spread="4.116"/>
                    <measurement group_id="B2" value="12.09" spread="5.672"/>
                    <measurement group_id="B3" value="11.01" spread="4.534"/>
                    <measurement group_id="B4" value="10.30" spread="3.902"/>
                    <measurement group_id="B5" value="10.85" spread="4.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.91" spread="28.165"/>
                    <measurement group_id="B2" value="90.30" spread="22.753"/>
                    <measurement group_id="B3" value="81.77" spread="18.977"/>
                    <measurement group_id="B4" value="83.27" spread="21.929"/>
                    <measurement group_id="B5" value="87.54" spread="23.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.75" spread="8.812"/>
                    <measurement group_id="B2" value="29.11" spread="6.291"/>
                    <measurement group_id="B3" value="27.85" spread="6.461"/>
                    <measurement group_id="B4" value="27.42" spread="7.486"/>
                    <measurement group_id="B5" value="28.83" spread="7.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Location of Common Warts</title>
          <units>each</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Left Hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Arm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Leg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Foot (excluding sole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Foot (excluding sole)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area of Primary Injected Wart</title>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.19" lower_limit="9.4" upper_limit="233.3"/>
                    <measurement group_id="B2" value="41.47" lower_limit="7.1" upper_limit="238.8"/>
                    <measurement group_id="B3" value="36.95" lower_limit="7.1" upper_limit="150.8"/>
                    <measurement group_id="B4" value="27.66" lower_limit="7.1" upper_limit="92.3"/>
                    <measurement group_id="B5" value="34.68" lower_limit="7.1" upper_limit="238.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of Primary Injected Wart(s)</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228.9" lower_limit="12" upper_limit="1560"/>
                    <measurement group_id="B2" value="202.0" lower_limit="14" upper_limit="1040"/>
                    <measurement group_id="B3" value="174.7" lower_limit="16" upper_limit="1092"/>
                    <measurement group_id="B4" value="196.8" lower_limit="12" upper_limit="670"/>
                    <measurement group_id="B5" value="201.3" lower_limit="12" upper_limit="1560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>45 weeks</time_frame>
        <population>Modified Intent to Treat (mITT) - subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>Modified Intent to Treat (mITT) - subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0329</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.5706</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0184</ci_lower_limit>
            <ci_upper_limit>2.4223</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.8926</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2722</ci_lower_limit>
            <ci_upper_limit>2.8156</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.7319</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1602</ci_lower_limit>
            <ci_upper_limit>2.5854</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Complete Resolution of All Common Warts at Any Treatment or Follow-up Visit</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>45 weeks</time_frame>
        <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Complete Resolution of All Common Warts at Any Treatment or Follow-up Visit</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4307</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.3828</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6191</ci_lower_limit>
            <ci_upper_limit>3.0883</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.8908</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4169</ci_lower_limit>
            <ci_upper_limit>5.8978</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0451</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>3.0000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9281</ci_lower_limit>
            <ci_upper_limit>9.6975</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Complete Resolution of Primary Injected Wart(s) at the 4 Month Follow-up Visit</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>4 month follow up visit at 45 weeks</time_frame>
        <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complete Resolution of Primary Injected Wart(s) at the 4 Month Follow-up Visit</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Injection Visits Needed to Obtain Complete Resolution of the Primary Injected Wart(s)</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>45 weeks</time_frame>
        <population>mITT. Subjects that received at least one post baseline measurement of the primary wart(s). Cohort 3 values represent resolution of largest primary wart</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Injection Visits Needed to Obtain Complete Resolution of the Primary Injected Wart(s)</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>mITT. Subjects that received at least one post baseline measurement of the primary wart(s). Cohort 3 values represent resolution of largest primary wart</population>
          <units>injection visits</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="10" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O3" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O4" value="4" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>2.7553</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4211</ci_lower_limit>
            <ci_upper_limit>5.3419</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>3.1516</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6148</ci_lower_limit>
            <ci_upper_limit>6.1509</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>3.3257</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7263</ci_lower_limit>
            <ci_upper_limit>6.4070</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Injection Visits for &gt;50% Reduction in Area of the Primary Injected Wart(s)</title>
        <time_frame>45 weeks</time_frame>
        <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Injection Visits for &gt;50% Reduction in Area of the Primary Injected Wart(s)</title>
          <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>injection visits</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="1.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Injection Visits to &gt;50% Reduction in the Total Area of All Measured Warts</title>
        <time_frame>45 weeks</time_frame>
        <population>mITT - Subjects that received at least on post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Injection Visits to &gt;50% Reduction in the Total Area of All Measured Warts</title>
          <population>mITT - Subjects that received at least on post baseline measurement of the primary wart(s)</population>
          <units>injection visits</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="8.0" upper_limit="NA">Value cannot be estimated due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="5.0" lower_limit="4.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Scarring at the Site of Resolved Primary and Non-primary Injected Wart(s)</title>
        <description>Scarring at any visit, many reports were transient being noted at only one or two visits and noted as resolving during the course of the study</description>
        <time_frame>45 weeks</time_frame>
        <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Scarring at the Site of Resolved Primary and Non-primary Injected Wart(s)</title>
          <description>Scarring at any visit, many reports were transient being noted at only one or two visits and noted as resolving during the course of the study</description>
          <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hypopigmentation at the Site of Resolved Primary and Non-primary Injected Wart(s)</title>
        <time_frame>45 weeks</time_frame>
        <population>Only mITT subjects with complete resolution of warts included in this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hypopigmentation at the Site of Resolved Primary and Non-primary Injected Wart(s)</title>
          <population>Only mITT subjects with complete resolution of warts included in this endpoint</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Injection Site Reactions With Frequency Greater Than 5%</title>
        <time_frame>45 weeks</time_frame>
        <population>Safety Population- All randomized subjects who received at least one intralesional dose of study medication. Subjects experiencing multiple types of reactions were counted once for each type, but only once across all reactions.</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Injection Site Reactions With Frequency Greater Than 5%</title>
          <population>Safety Population- All randomized subjects who received at least one intralesional dose of study medication. Subjects experiencing multiple types of reactions were counted once for each type, but only once across all reactions.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis/Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema/Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema/Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peeling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association Between the Age of the Largest Primary Injected Wart and Complete Resolution of the Largest Primary Injected Wart</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>45 weeks</time_frame>
        <population>mITT- Subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between the Age of the Largest Primary Injected Wart and Complete Resolution of the Largest Primary Injected Wart</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>mITT- Subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>number of warts resolved</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for complete resolution status of largest primary injected wart (yes vs no) with wart age as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4824</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.999</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.001</ci_upper_limit>
            <estimate_desc>An odds ratio &lt; 1 indicates that the age of the wart is negatively correlated with positive treatment outcome and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for complete resolution status of largest primary injected wart (yes vs no) with wart age as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.998</ci_lower_limit>
            <ci_upper_limit>1.004</ci_upper_limit>
            <estimate_desc>An odds ratio &lt; 1 indicates that the age of the wart is negatively correlated with positive treatment outcome and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for complete resolution status of largest primary injected wart (yes vs no) with wart age as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0219</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.993</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.987</ci_lower_limit>
            <ci_upper_limit>0.999</ci_upper_limit>
            <estimate_desc>An odds ratio &lt; 1 indicates that the age of the wart is negatively correlated with positive treatment outcome and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for complete resolution status of largest primary injected wart (yes vs no) with wart age as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8267</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.995</ci_lower_limit>
            <ci_upper_limit>1.004</ci_upper_limit>
            <estimate_desc>An odds ratio &lt; 1 indicates that the age of the wart is negatively correlated with positive treatment outcome and vice versa.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Association Between the Age of the Primary Injected Wart and the Recurrence of Any Resolved Wart at Any Visit.</title>
        <time_frame>45 weeks</time_frame>
        <population>mITT - subjects that received at least one post baseline measurement of the primary wart(s)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O4">
            <title>Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between the Age of the Primary Injected Wart and the Recurrence of Any Resolved Wart at Any Visit.</title>
          <population>mITT - subjects that received at least one post baseline measurement of the primary wart(s)</population>
          <units>wart recurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for recurrence status of any resolved wart (yes vs no) with age of the largest primary injected wart as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1657</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.964</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.915</ci_lower_limit>
            <ci_upper_limit>1.015</ci_upper_limit>
            <estimate_desc>An odds ratio &gt; 1 indicates that the age of the largest primary injected wart is positively correlated with the recurrence of any resolved wart and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for recurrence status of any resolved wart (yes vs no) with age of the largest primary injected wart as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8168</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.003</ci_upper_limit>
            <estimate_desc>An odds ratio &gt; 1 indicates that the age of the largest primary injected wart is positively correlated with the recurrence of any resolved wart and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for recurrence status of any resolved wart (yes vs no) with age of the largest primary injected wart as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4183</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.998</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.993</ci_lower_limit>
            <ci_upper_limit>1.003</ci_upper_limit>
            <estimate_desc>An odds ratio &gt; 1 indicates that the age of the largest primary injected wart is positively correlated with the recurrence of any resolved wart and vice versa.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Using a logistic regression model for recurrence status of any resolved wart (yes vs no) with age of the largest primary injected wart as a covariate.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5572</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.001</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.006</ci_upper_limit>
            <estimate_desc>An odds ratio &gt; 1 indicates that the age of the largest primary injected wart is positively correlated with the recurrence of any resolved wart and vice versa.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Summary of Complete Resolution of the Largest Primary Wart and Type of Treatment History</title>
        <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
        <time_frame>45 weeks</time_frame>
        <population>mITT- Subjects that received at least one post baseline measurement of the primary wart(s). A subject may belong to more than one prior treatment types. As defined in the Statistical Analysis Plan, Cohorts 1 and 3 were combined for this exploratory endpoint (0.3 mL injected into each wart)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 and Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart (Cohort 1) and multiple common warts (Cohort 3)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Complete Resolution of the Largest Primary Wart and Type of Treatment History</title>
          <description>Complete resolution of a wart was defined as the absence of visible or measurable presence of the wart</description>
          <population>mITT- Subjects that received at least one post baseline measurement of the primary wart(s). A subject may belong to more than one prior treatment types. As defined in the Statistical Analysis Plan, Cohorts 1 and 3 were combined for this exploratory endpoint (0.3 mL injected into each wart)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Effect of the Treatment History on the Number of Recurrences of Resolved Primary Warts</title>
        <time_frame>45 weeks</time_frame>
        <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s). A subject may belong to more than one prior treatment types. As defined in the Statistical Analysis Plan, Cohorts 1 and 3 were combined for this exploratory endpoint (0.3 mL injected into each wart)</population>
        <group_list>
          <group group_id="O1">
            <title>Pooled Placebo</title>
            <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 and Cohort 3</title>
            <description>0.3 mL of CANDIN administered intralesionally in the largest common wart (Cohort 1) and multiple common warts (Cohort 3)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2</title>
            <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of the Treatment History on the Number of Recurrences of Resolved Primary Warts</title>
          <population>mITT - Subjects that received at least one post baseline measurement of the primary wart(s). A subject may belong to more than one prior treatment types. As defined in the Statistical Analysis Plan, Cohorts 1 and 3 were combined for this exploratory endpoint (0.3 mL injected into each wart)</population>
          <units>Number of warts</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cryotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Salicylic Acid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events during or after the first wart injection through the last visit, up to 45 weeks</time_frame>
      <desc>Incidence of Treatment Emergent, Non-Injection Site Reactions</desc>
      <group_list>
        <group group_id="E1">
          <title>Pooled Placebo</title>
          <description>0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
Placebo: 0.9% Sodium Chloride Injection USP (non-preserved)</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1</title>
          <description>0.3 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2</title>
          <description>0.5 mL of CANDIN administered intralesionally in the largest common wart
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3</title>
          <description>0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
CANDIN: Candida albicans Skin Test Antigen for Cellular Hypersensitivity</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis, Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Brain Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Mediastinal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MeDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Burney, PhD, MBA</name_or_title>
      <organization>Nielsen BioSciences Inc.</organization>
      <phone>858-571-2726</phone>
      <email>david@nielsenbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

